Last reviewed · How we verify
Cortisporin (NEOMYCIN)
Cortisporin (NEOMYCIN) is a small molecule aminoglycoside antibacterial developed by Monarch Pharms, targeting the transient receptor potential cation channel subfamily V member 1. It was FDA-approved in 1957 for various bacterial infections, including keratitis, blepharoconjunctivitis, and hepatic encephalopathy. As an off-patent medication, Cortisporin is available from multiple generic manufacturers. Key safety considerations include its low bioavailability of 3% and potential ototoxicity. Cortisporin is used to treat a range of bacterial infections.
At a glance
| Generic name | NEOMYCIN |
|---|---|
| Sponsor | Pfizer |
| Drug class | Aminoglycoside Antibacterial |
| Target | Transient receptor potential cation channel subfamily V member 1 |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1957 |
Approved indications
- Bacterial keratitis
- Blepharoconjunctivitis
- Corneal abrasion
- Hepatic coma
- Hepatic encephalopathy
- Infective blepharitis
- Keratitis
- Mastoidectomy Cavity Infections
- Minor Bacterial Skin Infections
- Minor Skin Wound Pain
- Otitis externa
- Preoperative Bowel Preparation
- Superficial Ocular Infection
- Urinary tract infectious disease
- Uveitis
Common side effects
- Allergic contact dermatitis
- Allergic skin reactions
- Skin sensitization
- Itching
- Burning
- Irritation
- Dryness
- Folliculitis
- Hypertrichosis
- Acneiform eruptions
- Hypopigmentation
- Perioral dermatitis
Serious adverse events
- Ototoxicity
- Nephrotoxicity
Drug interactions
- pancuronium
- pipecuronium
- rocuronium
- suxamethonium
- tubocurarine
- vecuronium
Key clinical trials
- Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure (PHASE1)
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- Comparing No Mechanical Bowel Preparation With Oral Antibiotics Alone in Patients Undergoing Elective Colon Surgery (PHASE4)
- Intestinal Microbiome Transplant in ALS (PHASE1,PHASE2)
- Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders (PHASE2)
- Do Topical Antibiotics Improve Skin Graft Results?
- Antibiotics and Vaccine Immune Responses Study (PHASE4)
- Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cortisporin CI brief — competitive landscape report
- Cortisporin updates RSS · CI watch RSS
- Pfizer portfolio CI